Stockscreener 앱 받기
6.02
0.82%
-0.11
Agenus Inc 주식(AGEN)의 최신 뉴스
AGEN|Agenus Inc|Price:6.135|Chg%:+0.155 - TradingKey
BlackRock (AGEN) discloses 2.51M-share, 6% stake in Agenus common stock - Stock Titan
Agenus Inc (AGEN) Balance Sheet - TradingKey
Agenus Inc (AGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Agenus Inc (AGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
AGEN|Agenus Inc|Price:5.980|Chg%:-0.210 - TradingKey
Agenus Inc (AGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Agenus Inc (AGEN) Cash Flow - TradingKey
Agenus Inc. Revenue Breakdown – NASDAQ:AGEN - TradingView
Agenus Inc. (Nasdaq: AGEN) Q2 2025 Earnings Call | 08/27/2025 Brett Kulak (luI2X2n2sY) - Mshale
AGEN Stock MASSIVE NEWS!? (Thank Me Later Bro) Agenus Stock Best Broker Review Bp (nGoDV3hD3d) - Mshale
Agenus Inc. (AGEN) stock price, news, quote and history - Yahoo Finance UK
Agenus Inc (AGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in Agenus Inc - GuruFocus
Agenus Inc. (AGEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Do Options Traders Know Something About Agenus Stock We Don't? - Yahoo Finance
Agenus: More Shares, Fresh Starts, And Executive Pay Under The Microscope Sportitalia (bXVgSS8OPp) - Mshale
Agenus Analysis: Strategic Pivot And Financing Valuation Report AGEN $AGEN #AGEN #stockmarket See No Evil Bafta (mAryLCXecM) - Mshale
Agenus Analysis: Strategic Pivot And Financing Valuation Report AGEN $AGEN #AGEN #stockmarket Incendio Montesilvano (bwWkwlpOZa) - Mshale
Agenus Will Present Three Neoajuvant Studies at ESMO26 - Oncodaily
RA Capital and affiliates (NASDAQ: AGEN) disclose 9.99% beneficial ownership in Agenus - Stock Titan
Agenus (AGEN) Registration filing Summary - Quartr
Agenus (NASDAQ: AGEN) registers 2.13M previously issued shares for resale - Stock Titan
Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026 - BioSpace
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026 - 뉴스와이어
Agenus Inc.AGEN Stock Chart Technical Analysis For 03-09-2020 Giro D'italia (XPKerZ1996) - Mshale
My Take On Agenus's Cash Burn & Legal Risk Keldon Johnson (KIhGnPaajk) - Mshale
Inside the ROBBIN Phase 3 Strategy: Bringing BOT+BAL Into the Neoadjuvant Setting - Oncodaily
Agenus Inc. (AGEN) investors disclose 4.53M-share stake capped at 9.99% - Stock Titan
Agenus Inc. (Nasdaq: AGEN) Q2 2025 Earnings Call | 08/27/2025 Vocm News (LGDv0nXjs0) - Mshale
Agenus abstracts on cancer drug combo accepted at ESMO 2026 - Investing.com
Agenus abstracts on cancer drug combo accepted at ESMO 2026 By Investing.com - Investing.com UK
🔴 Agenus Inc. AGEN Stock Trading Facts 🔴 Gianna Nannini (cYwfB9Crlv) - Mshale
Why Agenus (AGEN Stock) Just Rocketed Up—Buy Now Or Too Late? Grêmio Vs Flamengo (4gW3JuWkOx) - Mshale
A.G.E.N.U.S. 8-K: My Take On The C.F.I.U.S. Delay Ctv News Ottawa (HFy9tZJhiU) - Mshale
Insider Trading AGEN Agenus Inc 2021 05 18 Blowing Dust Advisory (ETsN3n1J0C) - Mshale
Agenus Inc. (Nasdaq: AGEN) Q2 2025 Earnings Call | 08/27/2025 La Casa De Papel (vN5Dv9DbRJ) - Mshale
Agenus (AGEN) Could Be 83% Undervalued On Phase 1b Data And $340 Million Raise - Sahm
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer - 뉴스와이어
Agenus Surges 83% On $340 Million Financing: The Road To A 2030 Breakthrough (NASDAQ:AGEN) - Seeking Alpha
Agenus stock doubles as biotech narrows Phase 3 bet - AOL.com
Form 4 Agenus Inc For: 14 July By Investing.com - Investing.com Nigeria
Agenus Inc. (NASDAQ: AGEN) director takes 4,852-share stock salary grant - Stock Titan
AGEN Stock Pulls Back After Huge Spike As Traders Dig Into Financials - StocksToTrade
Agenus Announces Up to $340M Financing to Advance Phase 3 ROBBIN Trial in MSS Colon Cancer - Oncodaily
Jennifer S. Buell: Agenus’ Next Chapter in Early Immuno-Oncology With Phase 3 ROBBIN Trial - Oncodaily
From “Most Promising” to Phase 3: Up to $340M to Advance BOT/BAL in MSS Colon Cancer - Oncodaily
AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot - The Globe and Mail
Why Is Agenus Stock Falling on Tuesday? - Benzinga
Agenus Discontinues Phase 3 BATTMAN Trial in Metastatic MSS Colorectal Cancer - CancerNetwork
Zack Armen: A New Milestone for Agenus’ BOT+BAL Program in MSS Colon Cancer - Oncodaily
US Stocks Mixed; Dow Gains Over 100 Points - Sahm
Agenus announces up to $340M funding to advance registrational ROBBIN trial - The Pharma Letter
Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last? - Yahoo Finance
Agenus (AGEN) Reports Promising Results in Colorectal Cancer Tri - GuruFocus
Agenus (AGEN) Is Up 74.9% After Durable Botensilimab Combo Data In Refractory Colorectal CancerHas The Bull Case Changed? - Yahoo Finance
Agenus Stock Soars 83%, but $255 Million of Its $340 Million Lifeline Is Still Conditional - TechStock²
Agenus raises up to $340M to fund Phase 3 trial for colon cancer immunotherapy. - Pluang
Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS Colon CancerSlideshow (NASDAQ:AGEN) 2026-07-14 - Seeking Alpha
H.C. Wainwright raises Agenus stock price target to $30 on strategy shift - Investing.com UK
Oracle, Twin Vee PowerCats, Agenus, Micron Technology and SanDisk: Why These 5 Stocks Are on Investors' R - Benzinga
H.C. Wainwright raises Agenus stock price target to $30 on strategy shift By Investing.com - Investing.com South Africa
Agenus Announces Up to $340M Financing to Advance Phase 3 ROBBIN of Neoadjuvant BOT/BAL in MSS Colon Cancer - Oncodaily
Agenus (AGEN) Investor update Summary - Quartr
0.96%
0.92%
자본화:
|
볼륨(24시간):